

**SUPPLEMENTARY REFERENCES**

- S1. Kaivola K, Kiviharju A, Jansson L, et al. C9orf72 hexanucleotide repeat length in older population: normal variation and effects on cognition. *Neurobiol Aging*. 2019;84:242 e7- e12.
- S2. Farg MA, Sundaramoorthy V, Sultana JM, et al. C9ORF72, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. *Hum Mol Genet*. 2014;23(13):3579-95.
- S3. Braems E, Swinnen B, van den Bosch L. C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD? *Acta Neuropathol*. 2020;140(5):625-43.
- S4. Murphy NA, Arthur KC, Tienari PJ, et al. Age-related penetrance of the C9orf72 repeat expansion. *Sci Rep*. 2017;7(1):2116.
- S5. Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurol*. 2020;19(2):145-56.
- S6. Caswell C, McMillan CT, Xie SX, et al. Genetic predictors of survival in behavioral variant frontotemporal degeneration. *Neurology*. 2019;93(18):e1707-e14.
- S7. Woollacott IO, Mead S. The C9ORF72 expansion mutation: gene structure, phenotypic and diagnostic issues. *Acta Neuropathol*. 2014;127(3):319-32.
- S8. Rohrer JD, Isaacs AM, Mizielińska S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. *Lancet Neurol*. 2015;14(3):291-301.
- S9. Devenney E, Swinn T, Mioshi E, et al. The behavioural variant frontotemporal dementia phenocopy syndrome is a distinct entity - evidence from a longitudinal study. *BMC Neurol*. 2018;18(1):56.
- S10. Gómez-Tortosa E, Serrano S, de Toledo M, et al. Familial benign frontotemporal deterioration with C9ORF72 hexanucleotide expansion. *Alzheimers Dement*. 2014;10(5 Suppl):S284-9.
- S11. Suhonen NM, Kaivorinne AL, Moilanen V, et al. Slowly progressive frontotemporal lobar degeneration caused by the C9ORF72 repeat expansion: a 20-year follow-up study. *Neurocase*. 2015;21(1):85-9.
- S12. Kohli MA, John-Williams K, Rajbhandary R, et al. Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians. *Neurobiol Aging*. 2013;34(5):1519 e5-12.
- S13. Wojtas A, Heggeli KA, Finch N, et al. C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. *Am J Neurodegener Dis*. 2012;1(1):107-18.

- S14. Geiger JT, Arthur KC, Dawson TM, et al. C9orf72 Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies. *Neurodegener Dis*. 2016;16(5-6):370-2.
- S15. Kun-Rodrigues C, Ross OA, Orme T, et al. Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. *Neurobiol Aging*. 2017;49:214 e13- e15.
- S16. Forrest SL, Crockford DR, Sizemova A, et al. Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. *Neurology*. 2019;92(21):e2472-e82.
- S17. Ramos-Campoy O, Ávila-Polo R, Grau-Rivera O, et al. Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. *J Neuropathol Exp Neurol*. 2018;77(8):703-9.
- S18. Agosta F, Ferraro PM, Riva N, et al. Structural and functional brain signatures of C9orf72 in motor neuron disease. *Neurobiol Aging*. 2017;57:206-19.
- S19. Chiò A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. *Neurology*. 2019;93(10):e984-e94.
- S20. Abrahams S, Newton J, Niven E, et al. Screening for cognition and behaviour changes in ALS. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014;15(1-2):9-14.
- S21. van Rheenen W, van Blitterswijk M, Huisman MH, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. *Neurology*. 2012;79(9):878-82.
- S22. Galimberti D, Fenoglio C, Serpente M, et al. Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. *Biol Psychiatry*. 2013;74(5):384-91.
- S23. Kaivorinne AL, Bode MK, Paavola L, et al. Clinical Characteristics of C9ORF72-Linked Frontotemporal Lobar Degeneration. *Dement Geriatr Cogn Dis Extra*. 2013;3(1):251-62.
- S24. Landqvist Waldö M, Gustafson L, Nilsson K, et al. Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics. *Am J Neurodegener Dis*. 2013;2(4):276-86.
- S25. Snowden JS, Adams J, Harris J, et al. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. *Amyotroph Lateral Scler Frontotemporal Degener*. 2015;16(7-8):497-505.
- S26. Shinagawa S, Nakajima S, Plitman E, et al. Psychosis in frontotemporal dementia. *J Alzheimers Dis*. 2014;42(2):485-99.

- S27. Calvo A, Moglia C, Canosa A, et al. Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessive-compulsive disorder associated to GGGGCC expansion of the c9orf72 gene. *J Neurol*. 2012;259(12):2723-5.
- S28. Galimberti D, Reif A, Dell'Osso B, et al. C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. *Bipolar Disord*. 2014;16(4):448-9.
- S29. Holm AC. Neurodegenerative and psychiatric overlap in frontotemporal lobar degeneration: a case of familial frontotemporal dementia presenting with catatonia. *Int Psychogeriatr*. 2014;26(2):345-7.
- S30. Meisler MH, Grant AE, Jones JM, et al. C9ORF72 expansion in a family with bipolar disorder. *Bipolar Disord*. 2013;15(3):326-32.
- S31. Floris G, Borghero G, Di Stefano F, et al. Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred. *Amyotroph Lateral Scler Frontotemporal Degener*. 2016;17(3-4):245-8.
- S32. Majounie E, Abramzon Y, Renton AE, et al. Large C9orf72 repeat expansions are not a common cause of Parkinson's disease. *Neurobiol Aging*. 2012;33(10):2527 e1-2.
- S33. O'Dowd S, Curtin D, Waite AJ, et al. C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. *Mov Disord*. 2012;27(8):1072-4.
- S34. Goldman JS, Kuo SH. Multiple system atrophy and repeat expansions in C9orf72--reply. *JAMA Neurol*. 2014;71(9):1191-2.
- S35. Lindquist SG, Duno M, Batbayli M, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. *Clin Genet*. 2013;83(3):279-83.
- S36. Schipper LJ, Raaphorst J, Aronica E, et al. Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the C9ORF72 hexanucleotide repeat expansion: a systematic neuropathological review. *Neuropathol Appl Neurobiol*. 2016;42(6):547-60.
- S37. Xi Z, Zinman L, Grinberg Y, et al. Investigation of c9orf72 in 4 neurodegenerative disorders. *Arch Neurol*. 2012;69(12):1583-90.
- S38. Ida CM, Butz ML, Lundquist PA, et al. C9orf72 Repeat Expansion Frequency among Patients with Huntington Disease Genetic Testing. *Neurodegener Dis*. 2018;18(5-6):239-53.
- S39. Kostić VS, Dobričić V, Stanković I, et al. C9orf72 expansion as a possible genetic cause of Huntington disease phenocopy syndrome. *J Neurol*. 2014;261(10):1917-21.
- S40. Dewan R, Chia R, Ding J, et al. Pathogenic Huntingtin Repeat Expansion in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. *Neuron*. 2020.

- S41. Chio A, Battistini S, Calvo A, et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. *J Neurol Neurosurg Psychiatry*. 2014;85(5):478-85.
- S42. Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. *Genet Med*. 2017;19(3):267-74.
- S43. Turner MR, Al-Chalabi A, Chio A, et al. Genetic screening in sporadic ALS and FTD. *J Neurol Neurosurg Psychiatry*. 2017;88(12):1042-4.
- S44. Vajda A, McLaughlin RL, Heverin M, et al. Genetic testing in ALS: a survey of current practices. *Neurology*. 2017;88(10):991-9.
- S45. Arthur KC, Doyle C, Chio A, et al. Use of Genetic Testing in Amyotrophic Lateral Sclerosis by Neurologists. *JAMA Neurol*. 2017;74(1):125-6.
- S46. Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. *J Neurol*. 2019;266(8):2075-86.
- S47. Ducharme S, Bajestan S, Dickerson BC, et al. Psychiatric Presentations of C9orf72 Mutation: What Are the Diagnostic Implications for Clinicians? *J Neuropsychiatry Clin Neurosci*. 2017;29(3):195-205.
- S48. Dobson-Stone C, Hallupp M, Loy CT, et al. C9ORF72 repeat expansion in Australian and Spanish frontotemporal dementia patients. *PLoS One*. 2013;8(2):e56899.
- S49. García-Redondo A, Dols-Icardo O, Rojas-García R, et al. Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. *Hum Mutat*. 2013;34(1):79-82.
- S50. Bardelli D, Sassone F, Colombrita C, et al. Reprogramming fibroblasts and peripheral blood cells from a C9ORF72 patient: A proof-of-principle study. *J Cell Mol Med*. 2020;24(7):4051-60.
- S51. Zeier Z, Esanov R, Belle KC, et al. Bromodomain inhibitors regulate the C9ORF72 locus in ALS. *Exp Neurol*. 2015;271:241-50.
- S52. Waite AJ, Bäumer D, East S, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. *Neurobiol Aging*. 2014;35(7):1779 e5- e13.
- S53. Hantash FM, Goos DG, Tsao D, et al. Qualitative assessment of FMR1 (CGG)<sub>n</sub> triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening. *Genet Med*. 2010;12(3):162-73.

- S54. Fratta P, Poulter M, Lashley T, et al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. *Acta Neuropathol.* 2013;126(3):401-9.
- S55. Ramos EM, Dokuru DR, Van Berlo V, et al. Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. *Alzheimers Dement.* 2020;16(1):118-30.
- S56. Rollinson S, Bennion Callister J, Young K, et al. Small deletion in C9orf72 hides a proportion of expansion carriers in FTLD. *Neurobiol Aging.* 2015 Mar;36(3):1601.e1-5.
- S57. Buchman VL, Cooper-Knock J, Connor-Robson N, et al. Simultaneous and independent detection of C9ORF72 alleles with low and high number of GGGGCC repeats using an optimised protocol of Southern blot hybridisation. *Mol Neurodegener.* 2013;8:12.
- S58. Dashnow H, Lek M, Phipson B, et al. STRetch: detecting and discovering pathogenic short tandem repeat expansions. *Genome Biol.* 2018;19(1):121.
- S59. Mousavi N, Shleizer-Burko S, Yanicky R, et al. Profiling the genome-wide landscape of tandem repeat expansions. *Nucleic Acids Res.* 2019;47(15):e90.
- S60. Tang H, Kirkness EF, Lippert C, et al. Profiling of Short-Tandem-Repeat Disease Alleles in 12,632 Human Whole Genomes. *Am J Hum Genet.* 2017;101(5):700-15.
- S61. Tankard RM, Bennett MF, Degorski P, et al. Detecting Expansions of Tandem Repeats in Cohorts Sequenced with Short-Read Sequencing Data. *Am J Hum Genet.* 2018;103(6):858-73.
- S62. Dolzhenko E, Deshpande V, Schlesinger F, et al. ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. *Bioinformatics.* 2019;35(22):4754-6.
- S63. Rang FJ, Kloosterman WP, de Ridder J. From squiggle to basepair: computational approaches for improving nanopore sequencing read accuracy. *Genome Biol.* 2018;19(1):90.
- S64. Matsuura T, Fang P, Pearson CE, et al. Interruptions in the expanded ATTCT repeat of spinocerebellar ataxia type 10: repeat purity as a disease modifier? *Am J Hum Genet.* 2006;78(1):125-9.
- S65. Matsuyama Z, Izumi Y, Kameyama M, et al. The effect of CAT trinucleotide interruptions on the age at onset of spinocerebellar ataxia type 1 (SCA1). *J Med Genet.* 1999;36(7):546-8.
- S66. McFarland KN, Liu J, Landrian I, et al. Repeat interruptions in spinocerebellar ataxia type 10 expansions are strongly associated with epileptic seizures. *Neurogenetics.* 2014;15(1):59-64.
- S67. Menon RP, Nethisinghe S, Faggiano S, et al. The role of interruptions in polyQ in the pathology of SCA1. *PLoS Genet.* 2013;9(7):e1003648.

- S68. Pešović J, Perić S, Brkušanić M, et al. Repeat Interruptions Modify Age at Onset in Myotonic Dystrophy Type 1 by Stabilizing DMPK Expansions in Somatic Cells. *Front Genet.* 2018;9:601.
- S69. Russ J, Liu EY, Wu K, et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. *Acta Neuropathol.* 2015 Jan;129(1):39-52.
- S70. Liu EY, Russ J, Wu K, et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. *Acta Neuropathol.* 2014;128(4):525-41.
- S71. Xi Z, Rainero I, Rubino E, et al. Hypermethylation of the CpG-island near the C9orf72 G<sub>4</sub>C<sub>2</sub>-repeat expansion in FTLN patients. *Hum Mol Genet.* 2014;23(21):5630-7.
- S72. Xi Z, Zinman L, Moreno D, et al. Hypermethylation of the CpG island near the G<sub>4</sub>C<sub>2</sub> repeat in ALS with a C9orf72 expansion. *Am J Hum Genet.* 2013;92(6):981-9.
- S73. Xi Z, Zhang M, Bruni AC, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLN patients. *Acta Neuropathol.* 2015;129(5):715-27.
- S74. Lattante S, Millecamps S, Stevanin G, et al. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. *Neurology.* 2014;83(11):990-5.
- S75. Van Blitterswijk M, Mullen B, Heckman MG, et al. Ataxin-2 as potential disease modifier in C9orf72 expansion carriers. *Neurobiol Aging.* 2014;35(10):2421 e13-7.
- S76. Gallagher MD, Suh E, Grossman M, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. *Acta Neuropathol.* 2014;127(3):407-418.
- S77. Van Blitterswijk M, Mullen B, Nicholson AM, et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. *Acta Neuropathol.* 2014;127(3):397-406.
- S78. Zhang M, Ferrari R, Tartaglia MC, et al. A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. *Brain.* 2018;141(10):2895-2907.
- S79. Van Blitterswijk M, Baker MC, DeJesus-Hernandez M, et al. C9orf72 repeat expansions in cases with previously identified pathogenic mutations. *Neurology.* 2013;81(15):1332-41.
- S80. Gijssels I, Cruts M, Van Broeckhoven C. The Genetics of C9orf72 Expansions. *Cold Spring Harb Perspect Med.* 2018;8(4).
- S81. Ng ASL, Tan EK. Intermediate C9orf72 alleles in neurological disorders: does size really matter? *J Med Genet.* 2017;54(9):591-7.

S82. Cali CP, Patino M, Tai YK, et al. C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. *Acta Neuropathol.* 2019;138(5):795-811.